Norstella’s Post

Explore the forefront of pharmaceutical innovation with Norstella’s July roundup, featuring cutting-edge insights from industry trailblazers and learn about our brands' latest news and updates. Check out the links below. 👇 Pharma and biotech companies, including small biopharmas, are increasingly partnering with contract development and manufacturing organizations (CDMOs) to outsource drug development. Read the Norstella article: https://ow.ly/YKU150SOjuC. Citeline Clinical's PatientMatch is clinical research revolutionized. It’s a groundbreaking solution that uncovers the right patients and supercharges clinical trial enrollment. Learn about PatientMatch: https://ow.ly/KuUt50SOjux. The annual World Preview report from Evaluate Ltd is now live. Featuring pharma forecasts to 2030 and buckets of expert analysis on the data, the report provides fantastic insight into the therapy areas driving growth, the top companies and drugs, the market landscape and more. Download your copy now! https://ow.ly/UKRK50SOjuw Despite its cost, Wegovy is currently covered at 54% across all channels, according to MMIT (Managed Markets Insight & Technology)'s payer policy and restriction data. MMIT’s Autumn Bowman looks at coverage trends in this high-growth market: https://ow.ly/gmvg50SOjuA AI technology could be revolutionary for clinical trials, helping vastly reduce the cost of certain trial elements or even whole phases, writes Michael Munsell, PhD, Director of Research at Panalgo, in Pharmacy Times. https://ow.ly/OYat50SOjuB Unlock the power of market access success with PULSE Analytics by The Dedham Group. The robust dataset equips you to navigate market challenges with confidence. Learn how to proactively address emerging specialty market needs and optimize resource allocation for enhanced strategic planning: https://ow.ly/NjA950SOjuz. Follow our brands to stay up with the latest news, insights, and updates. #Pipeline2Patient #FollowNorstella

Title: Optimizing the Compass: Streamlining Clinical Trial Management and Monitoring for Biotech and Pharma Success Navigating the complexities of clinical trial management and monitoring (CTMM) is crucial for biotech and pharmaceutical companies seeking to bring life-saving treatments to patients. At eMIA, we recognize the evolving landscape of clinical trials and offer customized CTMM plans tailored to specific needs. Leveraging technology, such as cloud-based platforms and advanced analytics, optimizes data collection and analysis while ensuring regulatory compliance. However, the human touch remains indispensable, as our experienced clinical research professionals collaborate with clients to develop monitoring plans, assemble skilled trial teams, and foster clear communication channels. Investing in CTMM facilitates efficient trial execution, accelerates drug development timelines, and ultimately enhances patient access to vital treatments. Read the full article @ https://lnkd.in/eSu3ncrG

Explore the forefront of pharmaceutical innovation with Norstella’s October roundup, featuring cutting-edge insights from industry trailblazers and learn about our brands' latest news and updates. Check out the links below.👇 Norstella introduces NorstellaLinQ. It's biopharma’s first fully integrated data asset combining RWD—open and closed claims, lab results and EMR—with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data. Learn more: https://ow.ly/c1gV50TWN0U. Leveraging the power of AI, Citeline SmartSolutions products—Protocol SmartDesign and Investigator SmartSelect—help you reduce costly protocol amendments and increase predictability in clinical trial planning. See how Citeline SmartSolutions can help streamline your clinical planning process: https://ow.ly/xwlL50TWN0X. How can a biotech or smaller biopharma company get noticed by the right partners for out-licensing? An existing network can only take you so far, so Evaluate Ltd expert and BD&L consultant Ryan Lu, PhD, has shared the steps to help you put your best foot forward. https://ow.ly/zTIJ50TWN15 See how HCP Message Monitor by MMIT (Managed Markets Insight & Technology) helped a pharma manufacturer understand message effectiveness and ensure recall in its latest case study. https://ow.ly/ho4b50TWN1g Download this case study to see how Panalgo helped T1D Exchange unlock novel and impactful research areas in type 1 diabetes: https://ow.ly/xvHB50TWN12. Provider rebate aggregator business models are opaque, and their reach in the market has grown. Aaron McKeon-Fish and Arianna Noya from The Dedham Group cover what manufacturers need to know about provider rebate aggregators and their implications for their bottom line. https://ow.ly/RaNK50TWN0W Follow our brands to stay up with the latest news, insights, and updates. #Pipeline2Patient #FollowNorstella

See the link in the post below for a short summary of our webinar on early market access for biotech and investors #marketaccess #pharma #biotech

We're excited to launch our newest blog series, Mercalis at the Helm, where we navigate the most pressing issues in the life sciences industry. Our first post, "The Changing Landscape of Specialty Pharma Reimbursement in 2024," charts the course for understanding the key trends and challenges ahead. From evolving reimbursement models to regulatory shifts, discover what 2024 holds for stakeholders in specialty pharma. Join us as we steer through the complexities of the market. Read the first post here: https://bit.ly/3WA4GQL #MercalisAtTheHelm #SpecialtyPharma #LifeSciences

The pharmaceutical industry is undergoing a remarkable transformation, marked by technological innovation and evolving regulatory landscapes. These changes are setting the stage for the future of healthcare, ensuring that new treatments are safe, effective, and accessible. Discover more insights in the full article: https://lnkd.in/gidvuHCA #PharmaIndustry #Innovation #FutureOfHealthcare

Transform Patient Engagement at the 2nd Measuring Patient Engagement Summit with 70+ leaders from Pfizer, UCB, Novartis, AstraZeneca and more! Key Highlights: 💡 𝐄𝐗𝐀𝐌𝐈𝐍𝐄 frameworks driving patient-centered drug development with insights from UCB and Novartis. 💡 𝐂𝐎𝐋𝐋𝐀𝐁𝐎𝐑𝐀𝐓𝐄 in building actionable metrics with ISPEP, PFMD, and Alnylam Pharmaceuticals. 💡 𝐏𝐀𝐑𝐓𝐈𝐂𝐈𝐏𝐀𝐓𝐄 in workshops on patient advocacy, FDA alignment, and internal buy-in with Stemline Therapeutics, Mallinckrodt Pharmaceuticals, Omeros Corporation and PFMD. 💡 𝐍𝐀𝐕𝐈𝐆𝐀𝐓𝐄 standardized metric reporting from trials to commercialization with Pfizer, Eisai Co., Ltd., Spark Therapeutics, Inc. and others. 💡 𝐈𝐃𝐄𝐍𝐓𝐈𝐅𝐘 key metrics to prove patient engagement value to leadership, regulators, and patients. Learn to showcase the patient’s voice, strengthen trust, and drive life-changing treatments while aligning with regulatory needs. View the full event guide here: https://ter.li/zbkpqr 📅 Don’t miss the only event dedicated to measuring patient engagement success — register now: https://ter.li/zbkpqo #PatientEngagement #HealthcareInnovation #MeasuringWhatMatters

“NorstellaLinQ isn’t just about bringing together data,” said Mike Gallup, CEO of Norstella. https://ow.ly/pNyS50TGeO0 “It’s about creating the only solution in the market that links real-world patient data with the proprietary intelligence of Citeline, Evaluate, MMIT, Panalgo and The Dedham Group that have powered the pharmaceutical industry for decades.” Get closer to the patient than ever before. Learn more about NorstellaLinQ by Norstella at the link in this post. #Pipeline2Patient#FollowNorstella

Read then implement…

This case study describes how we tackled a significant challenge for a European pharmaceutical company focused on a rare pediatric disorder that was in phase III clinical trials. Our goal was to understand the UK’s current practices, standards of care, and market access requirements. What We Did: • Conducted a thorough analysis of disease incidence and unmet needs • Assessed current treatment guidelines and identified gaps • Mapped key stakeholders and treatment networks • Gathered insights from leading clinical experts and patient groups to refine product profiling • Provided expert connections to align regulatory processes with market strategies • Developed recommendations for pricing submissions and market access strategies Results: We clarified the next steps for market access, regulatory, and communications, ensuring the company was ready for market entry pending pivotal phase III results. Curious to learn more? Click the link to read the full case study https://lnkd.in/eUKkDChr #LifeSciences #Pharma #Marketentry #MarketAccess